Japan· JP-6239001M1022
クロファジミン
A clofazimine product containing クロファジミン, registered in Japan by ノバルティス ファーマ, on the national reimbursement list. The same ATC class is registered in 7 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Clofazimine is registered in 7 of 19 countries.
Countries holding a registration under ATC J04BA01 (clofazimine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Clofazimine · ATC J04BA01
7 / 19 countries
- Czechiaprice
- Franceprice
- Japan
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- クロファジミン
- Manufacturer
- ノバルティス ファーマ
- Country
- Japan (JP)
- ATC code
- J04BA01
- ATC class
- Clofazimine
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for clofazimine.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clofazimine · interactions on record
158 records
- 37 severe
- 119 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J04BA01
Clofazimine, as other registers publish it.
- United KingdomClofazimine 100mg capsulesSpecial Order
- United KingdomClofazimine 50mg capsulesSpecial Order
- SwitzerlandLampren 100 mg, KapselnNovartis Pharma Schweiz AG
- SwitzerlandLampren 50 mg, KapselnNovartis Pharma Schweiz AG
- United StatesLampreneNovartis Pharmaceuticals Corporation
- United StatesLampreneNovartis Pharmaceuticals Corporation
- NorwayLampreneNovartis
- CzechiaLAMPRENE
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dfe18ea9-f924-4011-b61c-a7a6c6f4b63d GET /v1/drugs/dfe18ea9-f924-4011-b61c-a7a6c6f4b63d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6239001M1022",
"category": "内用薬",
"price_yen": 149.2,
"generic_name": "クロファジミン",
"product_name_jp": null,
"therapeutic_class": "6239",
"transitional_expiry": null
}See everything about clofazimine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.